Sign In
Buy IDXG
$1.75
-0.0100 (-0.568%)
At Close: Jun 03, 2026
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
04:06pm, Tuesday, 12'th May 2026
Q1 Revenue of $9. 0 million Q1 Income from Continuing Operations of $0. 8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
04:06pm, Tuesday, 12'th May 2026
PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 a
Head to Head Contrast: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG)
02:30am, Friday, 24'th Apr 2026
Institutional and Insider Ownership 7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are owned by institutional investo
Head to Head Analysis: Dynatronics (NASDAQ:DYNT) versus Interpace Biosciences (OTCMKTS:IDXG)
04:24am, Thursday, 23'rd Apr 2026
Earnings and Valuation This table compares Dynatronics and Interpace Biosciences"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Pri
Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
03:22am, Tuesday, 21'st Apr 2026
Interpace Biosciences, Inc. (OTCMKTS:IDXG - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $1.41 and trad
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
04:01pm, Monday, 30'th Mar 2026
PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ended
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
12:12pm, Wednesday, 03'rd Dec 2025
PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan fa
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
04:01pm, Wednesday, 12'th Nov 2025
PARSIPPANY, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended Septemb
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
09:15am, Monday, 15'th Sep 2025
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molec
Interpace Biosciences Earnings Drop
04:41pm, Friday, 08'th Aug 2025
Interpace Biosciences Earnings Drop
Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace�
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
08:30am, Friday, 31'st Jan 2025
PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary financial and business results for the fi
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
06:30am, Monday, 27'th Jan 2025
PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification th
PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the final Lo
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
04:30pm, Monday, 04'th Nov 2024
PARSIPPANY, NJ, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended Septemb
